St. Jude Medical Inc. (NYSE:STJ) announced a med-tech first with a European CE Mark approval for its Genesis implanted neurostimulation device for patients with chronic migraines.
Genesis, which is the first device of its kind to win regulatory approval in any market, provides peripheral nerve stimulation to the occipital nerves to manage migraines. Small electrical leads are placed under the skin and connected to a device which produces pulses of stimulation.